Please login to the form below

Not currently logged in
Email:
Password:

Positive results from S-A diabetes trial

Sanofi-aventis has announced positive results from a phase III efficacy trial of once-daily lixisenatide versus twice-daily exenatide
Sanofi-aventis (S-A) has announced that results from a phase III trial comparing two GLP-1 receptor agonists in patients with type 2 diabetes showed once-daily lixisenatide achieved primary efficacy endpoint versus twice-daily exenatide. Early data also showed that that significantly fewer people with type 2 diabetes treated with lixisenatide once-daily reported hypoglycaemic events versus patients treated with exenatide. The study was measuring both lixisenatide and exenatide as add-on therapies for patients with type 2 diabetes whose condition is inadequately controlled by metformin.

Other endpoints measured during the GetGoal-X study were broadly consistent with what has been observed with other GLP-1 agonists. 

"GetGoal-X, the first head-to-head study comparing lixisenatide with another GLP-1, demonstrates the efficacy of lixisenatide once-daily in reducing HbA1c in people with type 2 diabetes and also shows a better hypoglycaemia profile," said Dr Andrew Hockey, director of medical operations, sanofi-aventis, UK.

"The lixisenatide clinical development programme exemplifies our commitment to people with diabetes and our ambition to help them manage their condition more effectively," he continued.

In April 2010, S-A reported positive results when lixisenatide was compared to placebo

Lixenatide was originally developed by Zealand Pharma who out-licensed the drug to S-A on a global basis in 2003, making S-A responsible for all further clinical development of the drug. In June 2010, the licensing deal was extended to see S-A take on the development and commercialisation of Lixisenatide in combination with Lantus (insulin glargine). Lantus is a recombinant human insulin analogue and was S-A's best selling treatment in 2009 with net sales of over €3bn. 

 

7th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics